Clinical Trials for Cervical Cancer

Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin-3 Inhibitor (GB1211) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with unresectable/metastatic melanoma (including mucosal/unknown primary; treatment-naïve allowed) or recurrent/metastatic HNSCC after platinum therapy are randomized to pembrolizumab plus GB1211 vs pembrolizumab plus placebo. GB1211 (selvigaltin) is an oral selective galectin‑3 inhibitor aimed at reversing immune suppression and resistance to PD‑1 blockade; prior PD‑1/PD‑L1 allowed if ≥6 months since last dose with progression; key exclusions include active autoimmune disease and untreated brain mets.

ClinicalTrials.gov ID: NCT05913388

A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: First-line study for adults with recurrent/metastatic, non-nasopharyngeal HNSCC (ECOG 0–1, measurable disease, no prior PD-1/TIGIT; prior curative-intent platinum allowed if relapse >6 months) comparing zimberelimab (anti–PD-1) plus carboplatin/paclitaxel with or without domvanalimab, an Fc-silent anti-TIGIT antibody that augments T-cell activity. Aims to determine whether adding anti-TIGIT to PD-1 blockade and platinum-taxane chemotherapy improves ORR and PFS.

ClinicalTrials.gov ID: NCT06727565

A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with recurrent/metastatic HPV-negative HNSCC after prior PD-1/PD-L1 inhibitor and platinum therapy (ECOG 0–1) are randomized to cetuximab plus ficlatuzumab vs cetuximab plus placebo. Ficlatuzumab is an anti-HGF monoclonal antibody that blocks HGF/MET signaling; prior EGFR inhibitor in the R/M setting is excluded.

ClinicalTrials.gov ID: NCT06064877

Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with RAF dimer–driven thyroid cancers: RAIR differentiated (papillary/follicular/Hürthle cell/poorly differentiated) with recent progression or anaplastic, harboring RAS or NF1 mutations, RET/NTRK/ALK fusions, or non‑V600E/K/class 2–3 BRAF alterations; ECOG 0–1, measurable disease, any prior lines, but no prior MEK/class II–III BRAF/FAK inhibitors. Treatment is oral avutometinib (dual RAF/MEK clamp) plus defactinib (FAK/Pyk2 inhibitor) on a 3-weeks-on/1-week-off schedule, with ORR as the primary endpoint.

ClinicalTrials.gov ID: NCT06007924

A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with PD-L1 CPS ≥1 recurrent or metastatic HNSCC (oral cavity, hypopharynx, larynx, or HPV-negative oropharynx), no prior systemic therapy for R/M disease, are randomized to pembrolizumab plus ficerafusp alfa (BCA101) vs pembrolizumab plus placebo. Ficerafusp alfa is a tumor-targeted bifunctional IgG1 that inhibits EGFR and locally traps TGF-β to enhance antitumor immunity; exclusions include active CNS mets, recent ICI, prior anti–TGF-β, most prior anti-EGFR mAbs, and autoimmune disease requiring systemic therapy.

ClinicalTrials.gov ID: NCT06788990

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Enrolling patients ≥10 years (≥30 kg) with unresectable/metastatic solid tumors or recurrent/progressive primary CNS tumors harboring qualifying BRAF alterations (class 1 V600E or class 2 incl. fusions), across cohorts for BRAF fusions, V600E CNS tumors, and selected rare V600E non‑CNS tumors; excludes NF1/activating RAS and prior MAPK inhibitors in most cohorts. Treatment is oral plixorafenib (PLX‑8394), a selective BRAF inhibitor that disrupts RAF dimer signaling and avoids paradoxical ERK activation, given alone or with cobicistat boosting depending on cohort.

ClinicalTrials.gov ID: NCT05503797

A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with metastatic or recurrent, non-curable HNSCC (oral cavity, oropharynx, hypopharynx, larynx) who progressed after anti–PD-1 and platinum therapy (ECOG 0–1, measurable disease) are randomized to petosemtamab (MCLA-158), a bispecific EGFR/LGR5 antibody that blocks EGFR signaling and promotes LGR5-mediated EGFR degradation with Fc effector activity, versus investigator’s choice single-agent therapy. Key endpoints are ORR and OS; excludes nasopharyngeal primaries and active CNS disease.

ClinicalTrials.gov ID: NCT06496178

A Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Single-arm study of zanzalintinib (XL092), an oral multikinase inhibitor of VEGFR2, MET, and TAM (TYRO3/AXL/MER), as first-line systemic therapy in adults with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer (papillary, follicular, oncocytic/Hürthle, or poorly differentiated) with RECIST-measurable disease and recent progression. Excludes prior systemic therapy in the RAI-refractory setting and patients with active brain mets or significant cardiovascular/GI risk; daily dosing in 21-day cycles until progression or toxicity.

ClinicalTrials.gov ID: NCT06959641

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial investigates APL-101, a selective c-MET receptor tyrosine kinase inhibitor, in adult patients with NSCLC exhibiting c-Met exon 14 skipping mutations, various solid tumors with MET alterations, and primary CNS tumors. It includes APL-101 monotherapy and combination therapy with EGFR inhibitors in cases of acquired MET amplification resistance.

ClinicalTrials.gov ID: NCT03175224

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with recurrent or metastatic solid tumors—including endometrial, head and neck, pancreatic, colorectal, hepatocellular, gastric, urothelial, ovarian, cervical, biliary tract, certain subtypes of breast cancer, and cutaneous melanoma—whose disease has progressed after standard therapy and who have measurable, biopsiable disease. All patients receive ifinatamab deruxtecan, an investigational B7-H3-directed antibody-drug conjugate delivering a topoisomerase I inhibitor, administered intravenously every three weeks.

ClinicalTrials.gov ID: NCT06330064